Construction of a frailty index as a novel health measure in systemic lupus erythematosus
(2020) In Journal of Rheumatology 47(1). p.72-81- Abstract
Objective. To construct a Frailty Index (FI) as a measure of vulnerability to adverse outcomes among patients with systemic lupus erythematosus (SLE), using data from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. Methods. The SLICC inception cohort consists of recently diagnosed patients with SLE followed annually with clinical and laboratory assessments. For this analysis, the baseline visit was defined as the first study visit at which sufficient information was available for construction of an FI. Following a standard procedure, variables from the SLICC database were evaluated as potential health deficits. Selected health deficits were then used to generate a SLICC-FI. The prevalence of frailty in... (More)
Objective. To construct a Frailty Index (FI) as a measure of vulnerability to adverse outcomes among patients with systemic lupus erythematosus (SLE), using data from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. Methods. The SLICC inception cohort consists of recently diagnosed patients with SLE followed annually with clinical and laboratory assessments. For this analysis, the baseline visit was defined as the first study visit at which sufficient information was available for construction of an FI. Following a standard procedure, variables from the SLICC database were evaluated as potential health deficits. Selected health deficits were then used to generate a SLICC-FI. The prevalence of frailty in the baseline dataset was evaluated using established cutpoints for FI values. Results. The 1683 patients with SLE (92.1% of the overall cohort) eligible for inclusion in the baseline dataset were mostly female (89%) with mean (SD) age 35.7 (13.4) years and mean (SD) disease duration 18.8 (15.7) months at baseline. Of 222 variables, 48 met criteria for inclusion in the SLICC-FI. Mean (SD) SLICC-FI was 0.17 (0.08) with a range from 0 to 0.51. At baseline, 27.1% (95% CI 25.0-29.2) of patients were classified as frail, based on SLICC-FI values > 0.21. Conclusion. The SLICC inception cohort permits feasible construction of an FI for use in patients with SLE. Even in a relatively young cohort of patients with SLE, frailty was common. The SLICC-FI may be a useful tool for identifying patients with SLE who are most vulnerable to adverse outcomes, but validation of this index is required prior to its use.
(Less)
- author
- organization
- publishing date
- 2020
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Cohort studies, Outcome assessment, Systemic lupus erythematosus
- in
- Journal of Rheumatology
- volume
- 47
- issue
- 1
- pages
- 10 pages
- publisher
- Journal of Rheumatology Publishing Company Limited
- external identifiers
-
- scopus:85077401794
- pmid:30988130
- ISSN
- 0315-162X
- DOI
- 10.3899/jrheum.181338
- language
- English
- LU publication?
- yes
- id
- 35ea5579-3bd0-4a93-a60e-1d8f675a42f0
- date added to LUP
- 2020-12-22 12:42:25
- date last changed
- 2024-04-17 22:28:56
@article{35ea5579-3bd0-4a93-a60e-1d8f675a42f0,
abstract = {{<p>Objective. To construct a Frailty Index (FI) as a measure of vulnerability to adverse outcomes among patients with systemic lupus erythematosus (SLE), using data from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. Methods. The SLICC inception cohort consists of recently diagnosed patients with SLE followed annually with clinical and laboratory assessments. For this analysis, the baseline visit was defined as the first study visit at which sufficient information was available for construction of an FI. Following a standard procedure, variables from the SLICC database were evaluated as potential health deficits. Selected health deficits were then used to generate a SLICC-FI. The prevalence of frailty in the baseline dataset was evaluated using established cutpoints for FI values. Results. The 1683 patients with SLE (92.1% of the overall cohort) eligible for inclusion in the baseline dataset were mostly female (89%) with mean (SD) age 35.7 (13.4) years and mean (SD) disease duration 18.8 (15.7) months at baseline. Of 222 variables, 48 met criteria for inclusion in the SLICC-FI. Mean (SD) SLICC-FI was 0.17 (0.08) with a range from 0 to 0.51. At baseline, 27.1% (95% CI 25.0-29.2) of patients were classified as frail, based on SLICC-FI values > 0.21. Conclusion. The SLICC inception cohort permits feasible construction of an FI for use in patients with SLE. Even in a relatively young cohort of patients with SLE, frailty was common. The SLICC-FI may be a useful tool for identifying patients with SLE who are most vulnerable to adverse outcomes, but validation of this index is required prior to its use.</p>}},
author = {{Legge, Alexandra and Kirkland, Susan and Rockwood, Kenneth and Andreou, Pantelis and Bae, Sang Cheol and Gordon, Caroline and Romero-Diaz, Juanita and Sanchez-Guerrero, Jorge and Wallace, Daniel J. and Bernatsky, Sasha and Clarke, Ann E. and Merrill, Joan T. and Ginzler, Ellen M. and Fortin, Paul and Gladman, Dafna D. and Urowitz, Murray B. and Bruce, Ian N. and Isenberg, David A. and Rahman, Anisur and Alarcon, Graciela S. and Petri, Michelle and Khamashta, Munther A. and Dooley, M. A. and Ramsey-Goldman, Rosalind and Manzi, Susan and Zoma, Asad A. and Aranow, Cynthia and MacKay, Meggan and Ruiz-Irastorza, Guillermo and Lim, S. Sam and Inanc, Murat and Van Vollenhoven, Ronald F. and Jonsen, Andreas and Nived, Ola and Ramos-Casals, Manuel and Kamen, Diane L. and Kalunian, Kenneth C. and Jacobsen, Soren and Peschken, Christine A. and Askanase, Anca and Hanly, John G.}},
issn = {{0315-162X}},
keywords = {{Cohort studies; Outcome assessment; Systemic lupus erythematosus}},
language = {{eng}},
number = {{1}},
pages = {{72--81}},
publisher = {{Journal of Rheumatology Publishing Company Limited}},
series = {{Journal of Rheumatology}},
title = {{Construction of a frailty index as a novel health measure in systemic lupus erythematosus}},
url = {{http://dx.doi.org/10.3899/jrheum.181338}},
doi = {{10.3899/jrheum.181338}},
volume = {{47}},
year = {{2020}},
}